comparemela.com

Latest Breaking News On - Matthew vincent dolan - Page 2 : comparemela.com

DexCom (DXCM) – Investment Analysts Weekly Ratings Updates

DexCom (NASDAQ: DXCM) recently received a number of ratings updates from brokerages and research firms: 5/1/2024 – DexCom was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating. 4/26/2024 – DexCom had its price target raised by analysts at Raymond James from $151.00 to $160.00. They now have a “strong-buy” rating […]

Savant Capital LLC Has $13 29 Million Stake in DexCom, Inc (NASDAQ:DXCM)

Savant Capital LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 3.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 107,120 shares of the medical device company’s stock after selling 3,941 shares during the […]

DexCom (NASDAQ:DXCM) Given New $160 00 Price Target at Raymond James

DexCom (NASDAQ:DXCM) Given New $160 00 Price Target at Raymond James
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

DexCom (NASDAQ:DXCM) Posts Earnings Results, Beats Estimates By $0 05 EPS

DexCom (NASDAQ:DXCM) Posts Earnings Results, Beats Estimates By $0 05 EPS
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

DexCom (NASDAQ:DXCM) PT Raised to $145 00

DexCom (NASDAQ:DXCM – Get Free Report) had its price objective raised by equities researchers at Canaccord Genuity Group from $144.00 to $145.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Canaccord Genuity Group’s price target points to a potential upside of […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.